Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
REGN Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call summary reflects strong financial performance with $848 million in revenue and growth potential driven by LIBTAYO and EYLEA HD. The Q&A session provides insights into strategic collaborations and product development, with management addressing concerns and emphasizing potential in various therapeutic areas. Despite some uncertainties, the company's robust pipeline and strategic initiatives, including share repurchases, suggest positive market sentiment. The absence of major negative factors and the focus on growth and shareholder returns support a positive stock price movement prediction.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
REGN Slides
Regeneron Q1 2026 slides: Dupixent drives 19% revenue growth2026-04-29
Regeneron Q4 2025 slides: Dupixent growth drives revenue, EYLEA HD gains momentum2026-01-30
Regeneron Q3 2025 slides: Dupixent drives growth as pipeline expands2025-10-28
Regeneron Q2 2025 slides: revenue rebounds to $3.68B after Q1 miss2025-08-01
REGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
